TGF Beta Receptors
Transforming growth factor-beta 1-3 (TGFβ) are members of a large multifunctional regulatory polypeptide family that controls cellular functions including proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immune surveillance, a
- PDF / 80,495 Bytes
- 7 Pages / 439.37 x 666.142 pts Page_size
- 98 Downloads / 145 Views
Contents Target: Transforming Growth Factor-β (TGFβ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Biology of the Target . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Target Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Role of the Target in Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . High-Level Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Diagnostic, Prognostic, and Predictive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Preclinical Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Clinical Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Anticipated High-Impact Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 2 3 3 4 4 5 5 6 7 7
Abstract
Transforming growth factor-beta 1-3 (TGFβ) are members of a large multifunctional regulatory polypeptide family that controls cellular functions including proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immune surveillance, and survival in many cell types. In intact canonical TGFβ signaling, the binding of a TGFβ to the TGFβ type II receptor enables the formation of a heteromeric complex between TGFβ type I and type II receptors. The type I receptor is phosphorylated by the type II receptor serine/threonine kinase. The activated type I receptor phosphorylates receptor-activated Smads that complex with Smad 4. The Smad complexes translocate into the nucleus and regulate target gene transcription through direct or indirect interaction with DNAbinding transcription factors or coactivators. Tumors are resistant to growth inhibition by TGFβ due to inactivation of the TGFβ signaling pathway or aberrant B. Teicher (*) Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA e-mail: [email protected]; [email protected] # Springer Science+Busin
Data Loading...
